Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter de Boer

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Journal of Psychopharmacology (Oxford, England)|April 7, 2020
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trialKasper Recourt, Jasper van der Aart, Gabriel Jacobs, et al.
European Journal of Radiology Open|March 4, 2016
Craniocaudal tumour extension in uterine cervical cancer on MRI compared to histopathologyPeter de Boer, Maaike C G Bleeker, Anje M Spijkerboer, et al.
Nature Genetics|January 24, 2007
Chromosome-wide nucleosome replacement and H3.3 incorporation during mammalian meiotic sex chromosome inactivationGodfried W van der Heijden, Alwin A H A Derijck, Eszter Pósfai, et al.
Journal of Psychopharmacology (Oxford, England)|January 16, 2019
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomniaSander Brooks, Gabriël E Jacobs, Peter de Boer, et al.
Journal of Psychopharmacology (Oxford, England)|February 1, 2012
In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomographyErik T te Beek, Peter de Boer, Matthijs Moerland, et al.
Biological Psychiatry|February 1, 2020
Peripheral Blood Cell-Stratified Subgroups of Inflamed DepressionMary-Ellen Lynall, Lorinda Turner, Junaid Bhatti, et al.
Journal of Psychopharmacology (Oxford, England)|June 1, 2018
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidityPeter De Boer, Wayne C Drevets, Hany Rofael, et al.
Human Reproduction (Oxford, England)|February 9, 2010
Sperm DNA: organization, protection and vulnerability: from basic science to clinical applications--a position reportChristopher L R Barratt, R John Aitken, Lars Björndahl, et al.
Magnetic Resonance in Medicine|April 22, 2020
Deep learning-based reconstruction of in vivo pelvis conductivity with a 3D patch-based convolutional neural network trained on simulated MR dataSoraya Gavazzi, Cornelis A T van den Berg, Mark H F Savenije, et al.
The American Journal of Psychiatry|April 9, 2016
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant DepressionJaskaran B Singh, Maggie Fedgchin, Ella J Daly, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Journal of Psychopharmacology (Oxford, England)|April 7, 2020
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trialKasper Recourt, Jasper van der Aart, Gabriel Jacobs, et al.
European Journal of Radiology Open|March 4, 2016
Craniocaudal tumour extension in uterine cervical cancer on MRI compared to histopathologyPeter de Boer, Maaike C G Bleeker, Anje M Spijkerboer, et al.
Nature Genetics|January 24, 2007
Chromosome-wide nucleosome replacement and H3.3 incorporation during mammalian meiotic sex chromosome inactivationGodfried W van der Heijden, Alwin A H A Derijck, Eszter Pósfai, et al.
Journal of Psychopharmacology (Oxford, England)|January 16, 2019
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomniaSander Brooks, Gabriël E Jacobs, Peter de Boer, et al.
Journal of Psychopharmacology (Oxford, England)|February 1, 2012
In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomographyErik T te Beek, Peter de Boer, Matthijs Moerland, et al.
Biological Psychiatry|February 1, 2020
Peripheral Blood Cell-Stratified Subgroups of Inflamed DepressionMary-Ellen Lynall, Lorinda Turner, Junaid Bhatti, et al.
Journal of Psychopharmacology (Oxford, England)|June 1, 2018
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidityPeter De Boer, Wayne C Drevets, Hany Rofael, et al.
Human Reproduction (Oxford, England)|February 9, 2010
Sperm DNA: organization, protection and vulnerability: from basic science to clinical applications--a position reportChristopher L R Barratt, R John Aitken, Lars Björndahl, et al.
Magnetic Resonance in Medicine|April 22, 2020
Deep learning-based reconstruction of in vivo pelvis conductivity with a 3D patch-based convolutional neural network trained on simulated MR dataSoraya Gavazzi, Cornelis A T van den Berg, Mark H F Savenije, et al.
The American Journal of Psychiatry|April 9, 2016
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant DepressionJaskaran B Singh, Maggie Fedgchin, Ella J Daly, et al.
Pageof 9